Regulation of heme oxygenase-1 by biliverdin reductase

胆绿素还原酶对血红素加氧酶-1 的调节

基本信息

  • 批准号:
    6892123
  • 负责人:
  • 金额:
    $ 22.44万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-07-15 至 2007-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Heme oxygenase (HO) activity is vital to a host of biological functions including cellular defense mechanisms, neuronal activity, vascular tone and male reproduction. The enzyme system oxidatively cleaves the heme molecule to biliverdin and carbon monoxide, a signal molecule. Biliverdin is reduced to bilirubin, an antioxidant, by biliverdin reductase (BVR). We have identified 3 HO isozymes: HO-1 (HSP-32), HO-2 and HO-3. HO-1 is exquisitely sensitive to environmental agents that cause oxidative stress and activate MAP kinase signal transduction pathways (e.g. 02 free radicals) as well as carcinogenesis and viral infections (e.g. Herpes, HIV). HO-2 and HO-3 are constitutively expressed. We have previously shown that HO-1 levels rapidly increase in response to oxidative stress both at the transcript and protein levels. The levels, however, rapidly decline with removal of the stimulus. Recently we identified HO-1 as a phosphoprotein. This type of protein modification can be of significance to protein stability and activity. Also, we discovered BVR to be a serine/threonine kinase and an activator of protein kinase C (PKC). PKC is upstream of the MAP kinase signaling pathway. On the other hand, we found that heme degradation product, biliverdin, is an in vivo inhibitor of HO activity and, a most effective inhibitor of PKC. Collectively, these findings lead us to hypothesize that a mechanism for the regulation of HO-1 expression by environmental oxidative stress involves both the kinase and the reductase activities of BVR: As a kinase, it activates the PKC/MAP kinase signaling pathway; and, as a reductase, it circumvents inhibition of the signaling pathway by biliverdin. We further hypothesize that phosphorylation is required for HO-1 activity and/or stability; hence, control of biliverdin production. These hypotheses will be tested by: 1) investigating the significance of HO-1 phosphorylation to its activity; and, examining whether rapid turnover of the induced HO-1 reflects a difference in its phosphorylation state under normal and induced conditions; 2) determining whether HO-1 is a phosphorylation substrate for BVR and/or PKC; 3) analyzing the regulatory role of BVR on induction of HO-1 gene expression through activation of the MAP kinase pathway; and; 4) assessing the effect of biliverdin on MAP kinase pathway activation. H202 will be utilized as the generator of 02 radicals. COS cells transfected with adenoviral vectors of effectors or their mutated counterparts will be used as the experimental model.
描述(由申请人提供):血红素加氧酶(HO)活性对许多生物功能至关重要,包括细胞防御机制、神经元活性、血管张力和男性生殖。酶系统将血红素分子氧化裂解为胆绿素和一氧化碳(信号分子)。胆绿素被胆绿素还原酶(BVR)还原为胆红素,一种抗氧化剂。我们鉴定了三种HO同工酶:HO-1(HSP-32),HO-2和HO-3。HO-1对引起氧化应激和激活MAP激酶信号转导途径(例如O2自由基)以及致癌和病毒感染(例如疱疹、HIV)的环境因子非常敏感。HO-2和HO-3组成型表达。我们以前已经表明,HO-1水平迅速增加,在转录和蛋白质水平的氧化应激反应。然而,随着刺激措施的取消,这一水平迅速下降。最近,我们确定HO-1作为磷蛋白。这种类型的蛋白质修饰对蛋白质的稳定性和活性具有重要意义。此外,我们发现BVR是一种丝氨酸/苏氨酸激酶和蛋白激酶C(PKC)的激活剂。PKC是MAP激酶信号通路的上游。另一方面,我们发现血红素降解产物胆绿素是体内HO活性的抑制剂,并且是最有效的PKC抑制剂。总的来说,这些研究结果使我们假设,HO-1表达的调节机制,环境氧化应激涉及的激酶和还原酶活性的BVR:作为一种激酶,它激活PKC/MAP激酶信号通路,并作为一种还原酶,它规避抑制信号通路的胆绿素。我们进一步假设磷酸化是HO-1活性和/或稳定性所必需的,因此,控制胆绿素的产生。这些假设将通过以下方式进行检验:1)研究HO-1磷酸化对其活性的意义;以及,检查诱导的HO-1的快速转换是否反映了其在正常和诱导条件下磷酸化状态的差异; 2)确定HO-1是否是BVR和/或PKC的磷酸化底物; 3)分析BVR对通过激活MAP激酶途径诱导HO-1基因表达的调节作用;和; 4)评估胆绿素对MAP激酶途径激活的作用。H2 O2将被用作O2自由基的发生器。用效应物或其突变对应物的腺病毒载体转染的COS细胞将用作实验模型。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mahin D. Maines其他文献

Mahin D. Maines的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mahin D. Maines', 18)}}的其他基金

Regulation of heme oxygenase-1 by biliverdin reductase
胆绿素还原酶对血红素加氧酶-1 的调节
  • 批准号:
    7847968
  • 财政年份:
    2009
  • 资助金额:
    $ 22.44万
  • 项目类别:
Heme Oxygenase-Regulation, Function&Clinical Application
血红素加氧酶调节、功能
  • 批准号:
    6556791
  • 财政年份:
    2003
  • 资助金额:
    $ 22.44万
  • 项目类别:
Regulation of heme oxygenase-1 by biliverdin reductase
胆绿素还原酶对血红素加氧酶-1 的调节
  • 批准号:
    7650440
  • 财政年份:
    2003
  • 资助金额:
    $ 22.44万
  • 项目类别:
Regulation of heme oxygenase-1 by biliverdin reductase
胆绿素还原酶对血红素加氧酶-1 的调节
  • 批准号:
    6945058
  • 财政年份:
    2003
  • 资助金额:
    $ 22.44万
  • 项目类别:
Regulation of heme oxygenase-1 by biliverdin reductase
胆绿素还原酶对血红素加氧酶 1 的调节
  • 批准号:
    8106400
  • 财政年份:
    2003
  • 资助金额:
    $ 22.44万
  • 项目类别:
Regulation of heme oxygenase-1 by biliverdin reductase
胆绿素还原酶对血红素加氧酶-1 的调节
  • 批准号:
    7496125
  • 财政年份:
    2003
  • 资助金额:
    $ 22.44万
  • 项目类别:
Regulation of heme oxygenase-1 by biliverdin reductase
胆绿素还原酶对血红素加氧酶 1 的调节
  • 批准号:
    7826827
  • 财政年份:
    2003
  • 资助金额:
    $ 22.44万
  • 项目类别:
Regulation of heme oxygenase-1 by biliverdin reductase
胆绿素还原酶对血红素加氧酶-1 的调节
  • 批准号:
    7319814
  • 财政年份:
    2003
  • 资助金额:
    $ 22.44万
  • 项目类别:
Regulation of heme oxygenase-1 by biliverdin reductase
胆绿素还原酶对血红素加氧酶-1 的调节
  • 批准号:
    7061316
  • 财政年份:
    2003
  • 资助金额:
    $ 22.44万
  • 项目类别:
Regulation of heme oxygenase-1 by biliverdin reductase
胆绿素还原酶对血红素加氧酶-1 的调节
  • 批准号:
    6777639
  • 财政年份:
    2003
  • 资助金额:
    $ 22.44万
  • 项目类别:

相似海外基金

Establishment of a Mouse NK Cell Line for Analyzing Tumor Infiltration Processes and Developing a Preclinical Model for Cancer Immunotherapy.
建立小鼠 NK 细胞系,用于分析肿瘤浸润过程并开发癌症免疫治疗的临床前模型。
  • 批准号:
    23K06731
  • 财政年份:
    2023
  • 资助金额:
    $ 22.44万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Proof of usefulness of PDX derived cell line
PDX 衍生细胞系的有用性证明
  • 批准号:
    23K06616
  • 财政年份:
    2023
  • 资助金额:
    $ 22.44万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A novel producer cell line for more efficient manufacturing of viral vector systems
用于更有效地制造病毒载体系统的新型生产细胞系
  • 批准号:
    10597799
  • 财政年份:
    2023
  • 资助金额:
    $ 22.44万
  • 项目类别:
Genestorian: a web application to document and trace genetic modifications in model organism and cell line collections.
Genestorian:一个网络应用程序,用于记录和追踪模型生物和细胞系集合中的遗传修饰。
  • 批准号:
    EP/Y024591/1
  • 财政年份:
    2023
  • 资助金额:
    $ 22.44万
  • 项目类别:
    Fellowship
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
  • 批准号:
    10672364
  • 财政年份:
    2022
  • 资助金额:
    $ 22.44万
  • 项目类别:
Developing a stable cell line expressing recombinant sclerostin
开发表达重组硬化素的稳定细胞系
  • 批准号:
    10385037
  • 财政年份:
    2022
  • 资助金额:
    $ 22.44万
  • 项目类别:
Development of Natural Killer (NK) Cell Line-Derived Extracellular Vesicles as a New Treatment for Cancer
开发自然杀伤 (NK) 细胞系衍生的细胞外囊泡作为癌症的新治疗方法
  • 批准号:
    10383462
  • 财政年份:
    2022
  • 资助金额:
    $ 22.44万
  • 项目类别:
A cell culture management platform to improve biomedical reproducibility by combining cell line tracking, low-cost genetic analysis, and riskassessment
细胞培养管理平台,通过结合细胞系追踪、低成本遗传分析和风险评估来提高生物医学重现性
  • 批准号:
    10483063
  • 财政年份:
    2022
  • 资助金额:
    $ 22.44万
  • 项目类别:
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
  • 批准号:
    10546865
  • 财政年份:
    2022
  • 资助金额:
    $ 22.44万
  • 项目类别:
Modulating expression of candidate genes to improve lentiviral vector production in stable cell line
调节候选基因的表达以提高稳定细胞系中慢病毒载体的产量
  • 批准号:
    2752732
  • 财政年份:
    2022
  • 资助金额:
    $ 22.44万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了